Methocinnamox
Names | |
---|---|
IUPAC name
(E)-N-[(4R,4aS,7aR,12bR)-3-(Cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-methylphenyl)prop-2-enamide
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
| |
| |
Properties | |
C30H32N2O4 | |
Molar mass | 484.596 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Methocinnamox is an opioid antagonist.
Mechanism of action
[edit]Methocinnamox is an opioid antagonist, it works at the μ-opioid receptor.[1] By being an antagonist, it binds to the receptor but does not activate it, thus blocking the action of agonists such as Fentanyl.
Therapeutic potential
[edit]Opioid overdose
[edit]In rats, methocinnamox is able to reverse the respiratory depressant effects of fentanyl. However, unlike naloxone, another opioid antagonist, its action lasts around 2 weeks if administered subcutaneously and up to 5 days if administered intravenously.[2] This could make it a better antidote than naloxone in opioid overdoses, because naloxone usually lasts around 30 minutes, there is a need for repeated administration and a danger of renarcotization.[3] By acting longer, methocinnamox prevents these dangers.
Other tests have also shown this result, methocinnamox was able to reverse the respiratory depressant effect of heroin.
References
[edit]- ^ Gerak, Lisa R.; Minervini, Vanessa; Latham, Elizabeth; Ghodrati, Saba; Lillis, Katherine V.; Wooden, Jessica; Disney, Alex; Husbands, Stephen M.; France, Charles P. (November 2019). "Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of μ-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in Rats". The Journal of Pharmacology and Experimental Therapeutics. 371 (2): 507–516. doi:10.1124/jpet.119.260331. ISSN 1521-0103. PMC 6863459. PMID 31439807.
- ^ Jimenez, Victor M.; Castaneda, Gabriel; France, Charles P. (April 2021). "Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats". The Journal of Pharmacology and Experimental Therapeutics. 377 (1): 29–38. doi:10.1124/jpet.120.000387. ISSN 1521-0103. PMC 7985616. PMID 33431611.
- ^ "Opioid Overdose Limitations in Naloxone Reversal". pubs.asahq.org. Retrieved 2024-02-11.